Certain cancers, such as osteosarcomas and soft-tissue sarcomas, have a high rate of TP53 mutation or downregulation, and novel approaches to treat cancers with TP53 abnormalities would play a critical role to improve patient outcome (16, 17). The gene discussed is TP53; the disease is soft tissue sarcoma.